The short answer
Avoid adding kava to oxazepam without prescriber review. Kava guidance advises against sedative co-use, despite studies in which a tested kava dose alone caused less impairment than oxazepam.
What this answer covers
Oral Piper methysticum; medicinal extract/cultivar doses are distinct from recreational quantities or mixtures.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- oxazepam
Why the precaution remains
NCCIH advises against combining kava with sedative substances. Oxazepam can impair alertness, so adding kava warrants review even when a particular kava dose did not impair volunteers on its own.
The driving trial tested separate exposures
Twenty-two adults took medicinal-dose kava, oxazepam or placebo on different occasions. Kava did not impair the measured driving outcomes, while oxazepam slowed braking. This does not show what happens when they are combined.
Dose and preparation limit the findings
The acute studies used a particular medicinal kava exposure. They cannot establish safety of larger recreational doses or a protective gap from oxazepam. Describe the exact product and regular use to the clinician.
Protect your alertness
Oxazepam can impair coordination and alertness. Avoid driving when affected. Seek urgent help for severe difficulty waking or breathing, and tell the prescriber about all other sedating medicines and alcohol.
Evidence and practical considerations
Side effects & toxicity
Conditional avoid/review is supported by official guidance and exact oxazepam CNS effects; negative kava-alone findings are retained as a limitation.
- Exact scope
- Oral Piper methysticum; medicinal extract/cultivar doses are distinct from recreational quantities or mixtures. with Exact oral oxazepam; no blanket benzodiazepine metabolic or route transfer.
- Medication form and route
- oral; other cannabis routes only if explicitly discussed
- Timing or duration
- Exact duration and dose depend on source; single-dose and chronic use are distinguished.
What remains uncertain
- Studies administered kava and oxazepam separately. No combined safety trial, universal product equivalence or validated spacing interval.
Factors that may matter: preparation and plant part; dose; other medicines; baseline alertness; clinical indication.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral oxazepam.
CNS depression, impaired coordination and alertness can occur; concomitant CNS depressants require caution. Dependence and withdrawal risks require individualized tapering rather than abrupt cessation. A single major inactive glucuronide metabolite is excreted in urine. CYP3A interactions measured with alprazolam cannot simply be assigned to oxazepam.
How this applies: Exact RxNorm ingredient and oral formulation confirmed in original label; use exact indication and metabolic boundaries.
Does not quantify the requested botanical interaction risks, prove every herb is sedating, or establish a protective supplement interval.
Source 2: official guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the specified supplement.
Advises against use with sedative substances. Kava may cause dizziness and has been linked to rare severe liver injury, including with different extraction methods.
How this applies: Preparation-specific context; not a directly measured oxazepam interaction.
Not a oxazepam study. Intrinsic liver risk does not establish added oxazepam hepatotoxicity; preparation and co-exposure vary.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Twenty-two adults in a randomized crossover driving study.
Medicinal-dose kava did not significantly impair driving outcomes; oxazepam impaired some outcomes.
How this applies: Apply only to exact medication, preparation and study exposure; comparator treatment is not co-use.
Not combined administration or evidence that all kava preparations lack impairment.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Participants in a controlled acute-dose crossover comparison.
Study compares mood and cognitive effects of individual treatments.
How this applies: Apply only to exact medication, preparation and study exposure; comparator treatment is not co-use.
Not a co-use trial; no claim of equivalent safety when combined.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact claims adjudicated against captured originals and explicit comparator/co-use boundaries. | |
| Research summary published |
Article revision: 6a17e7d18a9e120a
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.